Venous thromboembolism (VTE) is a frequent complication of cancer and carries a significant risk of mortality.1 Anticoagulation serves as the mainstay of treatment for VTE in patients with cancer and deep venous thrombosis (DVT) or pulmonary embolus (PE), but the associated risk of bleeding may be prohibitive in some patients. In this situation, or in a scenario wherein patients experience recurrent or progressive VTE despite anticoagulation, inferior vena cava (IVC) filters may be used as a means of mechanical thromboprophylaxis. Placement of an IVC filter itself, though, is not without risk. The evidence to support the use of IVC filters in patients with cancer, specifically, is limited.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Barnes JA, Goodney PP. Evidence Supporting the Use of Inferior Vena Cava Filters in Patients With Cancer—Coming Into Focus. JAMA Netw Open. 2020;3(7):e2011942. doi:10.1001/jamanetworkopen.2020.11942
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: